Peter J Neumann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7767994/publications.pdf

Version: 2024-02-01

160 papers	7,314 citations	76196 40 h-index	62479 80 g-index
167 all docs	167 docs citations	167 times ranked	8345 citing authors

#	Article	IF	Citations
1	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. JAMA - Journal of the American Medical Association, 2016, 316, 1093.	3.8	2,149
2	Legislating against Use of Cost-Effectiveness Information. New England Journal of Medicine, 2010, 363, 1495-1497.	13.9	222
3	Medicare and Cost-Effectiveness Analysis. New England Journal of Medicine, 2005, 353, 1516-1522.	13.9	219
4	Growth and Quality of the Costâ€"Utility Literature, 1976â€"2001. Value in Health, 2005, 8, 3-9.	0.1	136
5	Measuring the Value of Prescription Drugs. New England Journal of Medicine, 2015, 373, 2595-2597.	13.9	133
6	An Overview of Value, Perspective, and Decision Contextâ€"A Health Economics Approach: An ISPOR Special Task Force Report [2]. Value in Health, 2018, 21, 124-130.	0.1	132
7	Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists. Health Affairs, 2010, 29, 196-202.	2.5	125
8	A Health Economics Approach to US Value Assessment Frameworksâ€"Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health, 2018, 21, 161-165.	0.1	113
9	QALYs in 2018â€"Advantages and Concerns. JAMA - Journal of the American Medical Association, 2018, 319, 2473.	3.8	113
10	Willingnessâ€toâ€pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics (United Kingdom), 2012, 21, 238-251.	0.8	109
11	Perspective and Costing in Cost-Effectiveness Analysis, 1974â€"2018. Pharmacoeconomics, 2020, 38, 1135-1145.	1.7	109
12	Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value in Health, 2018, 21, 759-761.	0.1	108
13	Costing and Perspective in Published Cost-Effectiveness Analysis. Medical Care, 2009, 47, S28-S32.	1.1	107
14	MEASURING COSTS IN COST-UTILITY ANALYSES. International Journal of Technology Assessment in Health Care, 2000, 16, 111-124.	0.2	102
15	A Health Economics Approach to US Value Assessment Frameworksâ€"Introduction: An ISPOR Special Task Force Report [1]. Value in Health, 2018, 21, 119-123.	0.1	102
16	Cost-Effectiveness Analysis 2.0. New England Journal of Medicine, 2017, 376, 203-205.	13.9	100
17	The economic value of personalized medicine tests: what we know and what we need to know. Genetics in Medicine, 2014, 16, 251-257.	1.1	91
18	Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement. Health Affairs, 2011, 30, 2329-2337.	2.5	90

#	Article	IF	Citations
19	The Changing Face of the Cost-Utility Literature, 1990â€“2012. Value in Health, 2015, 18, 271-277.	0.1	85
20	Risk-Targeted Lung Cancer Screening. Annals of Internal Medicine, 2018, 168, 161.	2.0	85
21	Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis. Journal of the American Geriatrics Society, 2016, 64, 1549-1557.	1.3	82
22	Why don't Americans use cost-effectiveness analysis?. American Journal of Managed Care, 2004, 10, 308-12.	0.8	74
23	Is The United States Ready For QALYs?. Health Affairs, 2009, 28, 1366-1371.	2.5	69
24	Medicare and Medical Technology â€" The Growing Demand for Relevant Outcomes. New England Journal of Medicine, 2010, 362, 377-379.	13.9	69
25	When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLoS Medicine, 2017, 14, e1002397.	3.9	68
26	30 Years of Pharmaceutical Cost-Utility Analyses. Pharmacoeconomics, 2009, 27, 861-872.	1.7	67
27	Evidence-Based And Value-Based Formulary Guidelines. Health Affairs, 2004, 23, 124-134.	2.5	66
28	Dementia Diagnosis Disparities by Race and Ethnicity. Medical Care, 2021, 59, 679-686.	1.1	64
29	Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. Value in Health, 2019, 22, 661-668.	0.1	61
30	A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS ONE, 2016, 11, e0168512.	1.1	61
31	Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical Decision Making, 2018, 38, 767-777.	1.2	58
32	Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 685-698.	0.5	55
33	Review of Recent US Value Frameworksâ€"A Health Economics Approach: An ISPOR Special Task Force Report [6]. Value in Health, 2018, 21, 155-160.	0.1	52
34	The influence of time horizon on results of cost-effectiveness analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 615-623.	0.7	51
35	Should Health Insurance Cover Ivf? Issues and Options. Journal of Health Politics, Policy and Law, 1997, 22, 1215-1239.	0.9	50
36	Medicare's Enduring Struggle to Define â€œReasonable and Necessaryâ€•Care. New England Journal of Medicine, 2012, 367, 1775-1777.	13.9	49

#	Article	IF	Citations
37	Cost-Utility Analysis of Cancer Prevention, Treatment, and Control. American Journal of Preventive Medicine, 2016, 50, 241-248.	1.6	48
38	Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimerâ€™s Disease Interventions. Pharmacoeconomics, 2019, 37, 597-608.	1.7	46
39	Specialty Drug Coverage Varies Across Commercial Health Plans In The US. Health Affairs, 2018, 37, 1041-1047.	2.5	45
40	The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. Applied Health Economics and Health Policy, 2017, 15, 75-83.	1.0	44
41	Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1174-1178.	0.4	41
42	Can We Better Prioritize Resources for Cost-Utility Research?. Medical Decision Making, 2005, 25, 429-436.	1.2	40
43	Measuring the Value of Public Health Systems: The Disconnect Between Health Economists and Public Health Practitioners. American Journal of Public Health, 2008, 98, 2173-2180.	1.5	36
44	Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 632-642.	0.5	35
45	What Next for QALYs?. JAMA - Journal of the American Medical Association, 2011, 305, 1806.	3.8	34
46	Cost-Effectiveness Studies in the ICU: A Systematic Review*. Critical Care Medicine, 2019, 47, 1011-1017.	0.4	34
47	Growth and capacity for costâ€effectiveness analysis in Africa. Health Economics (United Kingdom), 2020, 29, 945-954.	0.8	34
48	Private Payers Disagree With Medicare Over Medical Device Coverage About Half The Time. Health Affairs, 2015, 34, 1376-1382.	2.5	33
49	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood, 2015, 125, 1866-1869.	0.6	32
50	Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. Value in Health, 2015, 18, 308-314.	0.1	32
51	Racial and Ethnic Differences in Knowledge About One's Dementia Status. Journal of the American Geriatrics Society, 2020, 68, 1763-1770.	1.3	32
52	A Review of Empirical Analyses of Disinvestment Initiatives. Value in Health, 2017, 20, 909-918.	0.1	29
53	Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. Journal of General Internal Medicine, 2020, 35, 2629-2636.	1.3	29
54	Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. Health Affairs, 2021, 40, 53-61.	2.5	29

#	Article	IF	Citations
55	Emerging Lessons From The Drug Effectiveness Review Project. Health Affairs, 2006, 25, W262-W271.	2.5	28
56	Therapies For Advanced CancersPose A Special Challenge For Health Technology Assessment Organizations In Many Countries. Health Affairs, 2012, 31, 700-708.	2.5	28
57	Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations. Health Affairs, 2015, 34, 253-260.	2.5	28
58	An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. PLoS ONE, 2015, 10, e0121715.	1.1	28
59	Economic Evaluation in the US. Pharmacoeconomics, 2006, 24, 1163-1168.	1.7	27
60	What We Talk about When We Talk about Health Care Costs. New England Journal of Medicine, 2012, 366, 585-586.	13.9	27
61	Adherence to the iDSI reference case among published cost-per-DALY averted studies. PLoS ONE, 2019, 14, e0205633.	1.1	27
62	Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia. JAMA Network Open, 2022, 5, e2216260.	2.8	27
63	How Long and How Well. Medical Decision Making, 2011, 31, 380-385.	1.2	26
64	Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. International Journal of Technology Assessment in Health Care, 2020, 36, 96-103.	0.2	26
65	Accelerating Alzheimer's disease drug innovations from the research pipeline to patients. Alzheimer's and Dementia, 2018, 14, 833-836.	0.4	25
66	Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. BMJ, The, 2020, 368, m141.	3.0	25
67	Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. Genetics in Medicine, 2022, 24, 1349-1361.	1.1	25
68	Health Utilities in Alzheimer???s Disease and Implications for Cost-Effectiveness Analysis. Pharmacoeconomics, 2005, 23, 537-541.	1.7	24
69	Cost-effectiveness of adherence-enhancing interventions: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 67-84.	0.7	24
70	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. Gates Open Research, 2018, 2, 5.	2.0	24
71	The History and Future of the â€œISPOR Value Flowerâ€• Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value in Health, 2022, 25, 558-565.	0.1	24
72	Skills of the Trade: The Tufts Cost-Effectiveness Analysis Registry. Journal of Benefit-Cost Analysis, 2012, 3, 1-9.	0.6	23

#	Article	IF	Citations
73	Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs. Health Affairs, 2014, 33, 1751-1760.	2.5	22
74	A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimerâ€™s Disease Patients. Neurology and Therapy, 2017, 6, 131-144.	1.4	22
75	Lessons for Health Technology Assessment: It Is Not Only about the Evidence. Value in Health, 2009, 12, S45-S48.	0.1	21
76	The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 931-940.	0.7	21
77	Drugs Cleared Through The FDAâ€™s Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process. Health Affairs, 2017, 36, 1408-1415.	2.5	20
78	Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. JAMA - Journal of the American Medical Association, 2020, 323, 1972.	3.8	20
79	Do HEDIS measures reflect cost-effective practices?. American Journal of Preventive Medicine, 2002, 23, 276-289.	1.6	19
80	Medicare's use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy, 2015, 119, 156-163.	1.4	19
81	Taking stock of cost-effectiveness analysis of healthcare in China. BMJ Global Health, 2019, 4, e001418.	2.0	19
82	Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. Value in Health, 2017, 20, 193-199.	0.1	18
83	Insurance coverage for genomic tests. Science, 2018, 360, 278-279.	6.0	18
84	Low-value services in value-based insurance design. American Journal of Managed Care, 2010, 16, 280-6.	0.8	18
85	A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. American Journal of Managed Care, 2008, 14, 185-8.	0.8	17
86	Communicating and Promoting Comparative-Effectiveness Research Findings. New England Journal of Medicine, 2013, 369, 209-211.	13.9	16
87	Patient Variability Seldom Assessed in Cost-effectiveness Studies. Medical Decision Making, 2018, 38, 487-494.	1.2	16
88	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. Gates Open Research, 2018, 2, 5.	2.0	15
89	The cost-effectiveness of biopharmaceuticals. MAbs, 2012, 4, 281-288.	2.6	14
90	The State of Cost-Utility Analyses in Asia: A Systematic Review. Value in Health Regional Issues, 2015, 6, 7-13.	0.5	14

#	Article	IF	Citations
91	Dementia diagnosis disparities by race and ethnicity. Alzheimer's and Dementia, 2020, 16, e043183.	0.4	14
92	Do drug formulary policies reflect evidence of value?. American Journal of Managed Care, 2006, 12, 30-6.	0.8	14
93	ICERâ€™s Revised Value Assessment Framework for 2017â€“2019: A Critique. Pharmacoeconomics, 2017, 35, 977-980.	1.7	13
94	Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage. Health Affairs, 2019, 38, 1882-1886.	2.5	13
95	Are low and middle-income countries prioritising high-value healthcare interventions?. BMJ Global Health, 2020, 5, e001850.	2.0	13
96	Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications. Value in Health, 2022, 25, 59-68.	0.1	13
97	International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. Journal of Clinical Oncology, 2016, 34, 2936-2937.	0.8	12
98	Measuring â€œFearonomic Effectsâ€•in Valuing Therapies: An Application to COVID-19 in China. Value in Health, 2020, 23, 1405-1408.	0.1	12
99	Preparing the healthâ€•care system to pay for new Alzheimer's drugs. Alzheimer's and Dementia, 2020, 16, 1568-1570.	0.4	12
100	An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. Journal of General Internal Medicine, 2021, 36, 3448-3455.	1.3	12
101	US FDA Modernization Act, Section 114. Pharmacoeconomics, 2011, 29, 687-692.	1.7	11
102	Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study. BMC Nephrology, 2015, 16, 67.	0.8	11
103	A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. Alzheimer's Research and Therapy, 2016, 8, 33.	3.0	11
104	Drug-Pricing Debate Redux â€” Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?. New England Journal of Medicine, 2021, 385, 1923-1924.	13.9	11
105	The Arrival of Economic Evidence in Managed Care Formulary Decisions. Medical Care, 2005, 43, II-27.	1.1	10
106	Oncologistsâ€™ and family physiciansâ€™ views on value for money of cancer and congestive heart failure care. Israel Journal of Health Policy Research, 2013, 2, 44.	1.4	10
107	A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues. Value in Health, 2022, 25, 1298-1306.	0.1	10
108	Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. Medical Decision Making, 2017, 37, 790-801.	1.2	9

#	Article	IF	Citations
109	Publication of Decision Model Source Code: Attitudes of Health Economics Authors. Pharmacoeconomics, 2019, 37, 1409-1410.	1.7	9
110	The Right Price. , 2021, , .		9
111	Modelling the value of innovative treatments for Alzheimerâ€™s disease in the United States. Journal of Medical Economics, 2021, 24, 764-769.	1.0	9
112	The lag from FDA approval to published cost-utility evidence. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 399-402.	0.7	8
113	The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. Health Research Policy and Systems, 2016, 14, 86.	1.1	8
114	Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. Pharmacoeconomics, 2016, 34, 1255-1265.	1.7	8
115	Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy. Pediatric Neurology, 2017, 66, 69-75.	1.0	8
116	Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients. Value in Health, 2018, 21, 304-309.	0.1	8
117	Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. Health Affairs, 2019, 38, 60-67.	2.5	8
118	The Economic and Public Health Imperatives Around Making Potential Coronavirus Diseaseâ€“2019 Treatments Available and Affordable. Value in Health, 2020, 23, 1427-1431.	0.1	8
119	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. Pharmacoeconomics, 2021, 39, 1201-1208.	1.7	8
120	A Call for Open-Source Cost-Effectiveness Analysis. Annals of Internal Medicine, 2018, 168, 529.	2.0	7
121	Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far. Journal of the American College of Radiology, 2020, 17, 452-461.	0.9	7
122	FDA Actions Against Health Economic Promotions, 2002â€“2011. Value in Health, 2012, 15, 948-953.	0.1	6
123	O2â€11â€01: National Estimates of Potentially Avoidable Hospitalizations among Medicare Beneficiaries with Alzheimer's Disease and Related Dementias. Alzheimer's and Dementia, 2016, 12, P253.	0.4	6
124	Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 164-173.	0.5	6
125	Comparative Modeling to Inform Health Policy Decisions: A Step Forward. Annals of Internal Medicine, 2019, 171, 851.	2.0	6
126	The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 494-508.	0.6	5

#	Article	IF	Citations
127	CHANGING FACE OF MEDICAREâ€™S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY. International Journal of Technology Assessment in Health Care, 2015, 31, 347-354.	0.2	5
128	Cost-Effectiveness Analysis Expands its Reach Worldwide. Value in Health Regional Issues, 2016, 10, 101-102.	0.5	5
129	Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1185-1192.	0.5	5
130	Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.. Oncologist, 2020, 25, e1117-e1119.	1.9	5
131	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine, 2021, 39, 6727-6734.	1.7	5
132	Lack of Cost-Effectiveness Analyses to Address Healthy People 2020 Priority Areas. American Journal of Public Health, 2016, 106, 2205-2207.	1.5	4
133	A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. Value in Health, 2018, 21, 400-406.	0.1	4
134	Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1240-1246.	0.5	4
135	For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 650-659.	0.5	4
136	Toward Better Data Dashboards for US Drug Value Assessments. Value in Health, 2021, 24, 1484-1489.	0.1	4
137	Valuing Alzheimer Disease Therapiesâ€”Considering Costs and Benefits Beyond the Patient. JAMA Network Open, 2021, 4, e2131913.	2.8	4
138	The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value in Health, 2022, 25, 1336-1343.	0.1	4
139	Estimating the Long Term Cost Savings from the Treatment of Alzheimer??s Disease: A Modelling Approach. Pharmacoeconomics, 2000, 17, 109.	1.7	3
140	A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 657-661.	0.7	3
141	When Does FDAMA Section 114 Apply? Ten Case Studies. Value in Health, 2015, 18, 682-689.	0.1	3
142	Updated Recommendations for Cost-effectiveness Studiesâ€”Reply. JAMA - Journal of the American Medical Association, 2017, 317, 90.	3.8	3
143	Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?. Value in Health, 2019, 22, 1396-1401.	0.1	3
144	Valueâ€based drug pricing in the Biden era: Opportunities and prospects. Health Services Research, 2021, 56, 1093-1099.	1.0	3

#	Article	IF	Citations
145	Evaluating HTA principles. International Journal of Technology Assessment in Health Care, 2010, 26, 429-430.	0.2	2
146	Is the US â€œleading from behindâ€•on health policy?. European Journal of Health Economics, 2014, 15, 113-116.	1.4	2
147	The Role of Decision Models in Health Care Policy. Medical Decision Making, 2016, 36, 666-679.	1.2	2
148	Addressing Challenges to Alternative Payment Models for New Alzheimerâ€™s Disease Therapies for US Commercial Payers. Pharmacoeconomics, 2022, 40, 647-652.	1.7	2
149	Are mAbs different?. MAbs, 2009, 1, 29-30.	2.6	1
150	P2-433: 30-Day Hospital Readmissions Among Medicare Beneficiaries With Alzheimerâ€™s Disease and Related Dementias Prior to and Following Diagnosis. , 2016, 12, P811-P812.		1
151	Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval. Applied Health Economics and Health Policy, 2017, 15, 227-235.	1.0	1
152	[P4â€“557]: FAMILY AND CAREGIVER SPILLOVER EFFECTS IN ALZHEIMER's DISEASE COSTâ€EFFECTIVENESS ANALYSES. Alzheimer's and Dementia, 2017, 13, P1565.	0.4	1
153	Risk-Targeted Lung Cancer Screening. Annals of Internal Medicine, 2018, 169, 200.	2.0	1
154	Is the high cost of CML care "worth it"?. Journal of Clinical Oncology, 2015, 33, e17801-e17801.	0.8	1
155	Are Medical Devices Cost-Effective?. Applied Health Economics and Health Policy, 2022, 20, 235-241.	1.0	1
156	Evaluating and Regulating Pharmacoeconomic Information in the Private Sector. Drug Information Journal, 1998, 32, 525-532.	0.5	0
157	Challenges Ahead For Federal Technology Assessment. Health Affairs, 2007, 26, w150-w152.	2.5	0
158	NEUMANN ET AL. RESPOND. American Journal of Public Health, 2009, 99, 776-776.	1.5	0
159	Price and value in cancer care. Cancer, 2015, 121, 4097-4098.	2.0	0
160	Costâ€“Utility Analysis. Annals of Internal Medicine, 2001, 134, 626.	2.0	0